In response to the release of ‘Potential role of circulating tumor DNA (ctDNA) in the early diagnosis and post-operative management of localised pancreatic cancer’ presented at the ASCO Annual Meeting in Chicago. Anna Jewell, Director of Operations at Pancreatic Cancer UK, said:
“We urgently need to find new ways to diagnose pancreatic cancer earlier. 80 per cent of people with the disease are diagnosed at an advanced stage, when surgery, the only treatment that can save lives, is not possible.
“Currently, there isn’t a reliable blood test to detect pancreatic cancer at an early stage and finding such a test would be a game changer for tackling the disease. This research looks promising as it has the potential to lead to a test to pick up pancreatic cancer earlier, in time for surgery to be an option. However, it is important to remember that any new screening tool would be several years away. We now need more research to be undertaken and for a larger study to be carried out to see if this research could lead to an effective early diagnosis tool for pancreatic cancer.”
For information about pancreatic cancer or Pancreatic Cancer UK, visit pancreaticcancer.org.uk/research